Corcept Therapeutics Incorporated
CORT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $675,040 | $482,375 | $401,858 | $365,978 |
| % Growth | 39.9% | 20% | 9.8% | – |
| Cost of Goods Sold | $10,882 | $6,481 | $5,385 | $5,281 |
| Gross Profit | $664,158 | $475,894 | $396,473 | $360,697 |
| % Margin | 98.4% | 98.7% | 98.7% | 98.6% |
| R&D Expenses | $246,887 | $184,353 | $130,991 | $113,864 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $280,320 | $184,259 | $152,848 | $122,356 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $527,207 | $368,612 | $283,839 | $236,220 |
| Operating Income | $136,951 | $107,282 | $112,634 | $124,477 |
| % Margin | 20.3% | 22.2% | 28% | 34% |
| Other Income/Exp. Net | $24,542 | $17,275 | $3,557 | $529 |
| Pre-Tax Income | $161,493 | $124,557 | $116,191 | $125,006 |
| Tax Expense | $20,284 | $18,417 | $14,773 | $12,494 |
| Net Income | $139,733 | $106,140 | $101,418 | $112,512 |
| % Margin | 20.7% | 22% | 25.2% | 30.7% |
| EPS | 1.35 | 1.02 | 0.95 | 0.97 |
| % Growth | 32.4% | 7.4% | -2.1% | – |
| EPS Diluted | 1.23 | 0.94 | 0.87 | 0.89 |
| Weighted Avg Shares Out | 103,232 | 103,560 | 106,787 | 115,653 |
| Weighted Avg Shares Out Dil | 113,480 | 111,742 | 115,966 | 125,963 |
| Supplemental Information | – | – | – | – |
| Interest Income | $24,542 | $17,275 | $3,557 | $529 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,336 | $1,042 | $1,259 | $3,067 |
| EBITDA | $138,287 | $108,324 | $113,893 | $127,953 |
| % Margin | 20.5% | 22.5% | 28.3% | 35% |